Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly is a top producer of insulin and antibiotics, and a growing force in weight loss drugs and treatments for Alzheimer’s. The company is also known for drugs to treat diabetes (Trulicity ...

2-Year U.S. Treasury Note Continuous Contract $102.758 0.031 0.03% 5-Year U.S. Treasury Note Continuous Contract $106.148 0.078 0.07% 10-Year U.S. Treasury Note Continuous Contract $108.469 0.094 ...

2-Year U.S. Treasury Note Continuous Contract $102.844-0.063-0.06% 5-Year U.S. Treasury Note Continuous Contract $106.383-0.180-0.17% 10-Year U.S. Treasury Note Continuous Contract $108.859-0.297 ...